Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide vs Radiotherapy in Low Grade Gliomas
NCT00182819Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2005
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of temozolomide in glioma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-Free Survival at 5 years. Started Jul 2005; status: completed.
02
Drugs
temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00182819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00182819.